ASN and Recent ESA Label Changes

Thomas H. Hostetter, MD
Wolfgang C. Winkelmayer, MD, ScD

American Society of Nephrology

Thursday, October 6, 2011
American Society of Nephrology

Representing more than 13,000 members—including physicians, scientists, and other health professionals—the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
Issue #1: Inaccuracy of key statement in Boxed Warning

“[…] In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1). […]”

✓ Available trial evidence does not support this statement. No trial targeted a hemoglobin concentration >11 g/dL.
### Issue #1: Inaccuracy of key statement in Boxed Warning

<table>
<thead>
<tr>
<th></th>
<th>Target hemoglobin g/dL</th>
<th>Achieved hemoglobin g/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>NHT</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>CREATE</td>
<td>11-12.5</td>
<td>13-15</td>
</tr>
<tr>
<td>CHOIR</td>
<td>11.3</td>
<td>13.5</td>
</tr>
<tr>
<td>TREAT</td>
<td>&gt;9 *</td>
<td>13</td>
</tr>
</tbody>
</table>

* Not a hemoglobin target, but a threshold group; placebo group with darbepoetin rescue below a hemoglobin concentration of 9 g/dL.
An accurate statement would read as follows:

“[…] In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 13 g/dL (5.1). […]”
Issue #2: Removal of the 10-12 g/dL Target Range

Since adverse events were consistently observed in randomization groups targeting hemoglobin concentrations >13 g/dL, no scientific data are currently available that would justify dropping the previous hemoglobin target of 10-12 g/dL.
New dosing recommendation terminology could result in overly conservative, more rigidly enacted ESA dosing practice patterns in some dialysis units, especially in light of recent coverage decisions by CMS. This change may place patients at increased risk of anemia and blood transfusions, which could adversely affect health and candidacy for transplantation.
Medicare Program; Changes to the End-Stage Renal Disease Prospective Payment System for CY 2012, End-Stage Renal Disease Quality Incentive Program for PY 2013 and PY 2014; Ambulance Fee Schedule; and Durable Medical Equipment

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Proposed rule.

[Safety/ucm259639.htm](#). We have discussed with the FDA our proposal to retire the Hemoglobin Greater Than 10 g/dL measure starting in PY 2013. Since this measure encourages providers to keep hemoglobin above 10 g/dL in all patients, the FDA agrees that removing this measure is consistent with the new labeling for erythropoiesis stimulating agents approved by the FDA. The previous labeling recommendations to maintain hemoglobin levels between 10 and 12 g/dL are no longer appropriate and have been removed from the drug label. We, therefore, **propose to retire the Hemoglobin Less Than 10g/dL measure from the ESRD QIP measure set, beginning with the PY 2013 program.**
Issue #4: Dose interruptions

“[… ] if the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of epogen. […]”

In chronic treatments we rarely consider interrupting treatment as it may lead to adverse health outcomes. In the setting of anemia in CKD patients, this may place patients at increased risk of transfusions.
Further research examining ESA doses at various hemoglobin levels is needed to elucidate the optimal course of ESA therapy.
1. Remove statement that “[…] In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1). […]” or alternatively, correct the statement to reflect the correct threshold “[…] to target a hemoglobin level of greater than 13 g/dL […]”

2. Consider reinstating recommended 10-12 g/dL target hemoglobin range until the further research examining ESA doses at various hemoglobin levels elucidates the optimal course of ESA therapy (or proves conclusively that >10 g/dL is an inappropriate target).
ASN Recommendations

3. Consider removing the word “interrupt” from the statement “[…] if the hemoglobin level approaches or exceeds 11 g/dL, reduce or **interrupt** the dose of epogen. […]”

4. Continue to work with CMS to ensure consistency between the policies and goals of the agencies pertaining to ESAs.

5. Recognize that more scientific evidence is necessary to understand the most appropriate use of ESAs.
For More Information, Please Contact

Rachel Nell Shaffer  
Policy and Government Affairs Manager  
American Society of Nephrology  
1510 H Street, NW  
Suite 800  
Washington, DC 20006  
(202) 640-4659  
rshaffer@asn-online.org